Coutinho J, Chorão R S, Oliveira M, Santos C R
Hospital Amato Lusitano, Castelo Branco, Portugal.
Centro Hospitalar Cova da Beira, Covilhã, Portugal.
Case Rep Nephrol. 2019 Mar 17;2019:6819476. doi: 10.1155/2019/6819476. eCollection 2019.
Tumor necrosis factor receptor associated periodic syndrome (TRAPS) is a rare monogenic autoinflammatory disease. Its most severe manifestation is secondary amyloidosis. A 44-year-old male presented with nephrotic syndrome. Kidney biopsy was conclusive for secondary amyloidosis. The patient and his children had a history of recurrent febrile periods since infancy. All subjects were positive for a heterozygous variant of the TNFRSF1A gene, confirming TRAPS diagnosis. The patient progressed to end-stage renal failure and developed recurrent pericarditis episodes. He was started on anakinra while on hemodialysis with marked reduction of his serum amyloid A protein (SAA) levels. Meanwhile he received a cadaveric renal transplant and maintains anakinra treatment. Despite renal failure being the most feared complication of AA amyloidosis caused by TRAPS, little data is available about safety of anti-IL-1 treatment in patients with severe kidney failure. The authors report this case of a patient on dialysis treated with anakinra in which no complications were registered. Though amyloidosis is established, the authors believe containing its progression and reducing inflammatory activity can improve patient prognosis and reduce recurrence of amyloidosis in kidney transplant, as has been demonstrated in transplanted patients due to familial Mediterranean fever amyloidosis.
肿瘤坏死因子受体相关周期性综合征(TRAPS)是一种罕见的单基因自身炎症性疾病。其最严重的表现是继发性淀粉样变性。一名44岁男性出现肾病综合征。肾脏活检确诊为继发性淀粉样变性。该患者及其子女自婴儿期起就有反复发热史。所有受试者TNFRSF1A基因杂合变异均呈阳性,确诊为TRAPS。该患者进展为终末期肾衰竭,并出现反复心包炎发作。他在血液透析期间开始使用阿那白滞素治疗,血清淀粉样蛋白A(SAA)水平显著降低。与此同时,他接受了尸体肾移植,并继续使用阿那白滞素治疗。尽管肾衰竭是TRAPS所致AA淀粉样变性最可怕的并发症,但关于抗IL-1治疗在严重肾衰竭患者中的安全性数据很少。作者报告了这例接受阿那白滞素治疗的透析患者,未记录到并发症。尽管淀粉样变性已确诊,但作者认为,控制其进展并降低炎症活性可改善患者预后,并减少肾移植中淀粉样变性的复发,正如在家族性地中海热淀粉样变性所致移植患者中所证明的那样。